Skip to main content
Explore URMC

Kristen M. O'Dwyer, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-4099

Fax: (585) 273-1051

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Hospital Medicine, Hematology & Oncology



Post-doctoral Training & Residency

07/01/2006 - 06/30/2010
Fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center

07/01/2005 - 06/30/2006
Residency in Internal Medicine at New York Presbyterian Hospital/Weill Cornell

06/14/2004 - 06/30/2005
Internship in Internal Medicine at New York Presbyterian Hospital/Weill Cornell

07/01/2003 - 06/30/2004
Internship in Pathology at National Cancer Institute/National Institute of Health

VIEW ALL expand_more


2016 - Present
Young Investigator Award
Sponsor: Southwest Oncology Group (SWOG)

2010 - 2013
Wilmot Cancer Research Fellowship
Sponsor: University of Rochester School of Medicine and Dentistry
Location: Rochester, NY

2009 - 2010
Young Investigator Award
Sponsor: ASCO Cancer Foundation

2007 - 2009
Clinical Scholars Biomedical Research Fellowship
Sponsor: Memorial Sloan-Kettering Cancer Center

2003 - 2004
National Institutes of Health General Research Loan Repayment Program
Sponsor: NIH

2002 - 2003
Howard Hughes Medical Institute Research Training Fellowship for Medical Students
Sponsor: Hughes

2000 - 2002
NIH Research Scholar, Cloister Program
Sponsor: Hughes

Medical Student Teaching Fellowship. Dept. of Physiology
Sponsor: University of Wisconsin School of Medicine
Location: Madison, WI

VIEW ALL expand_more

Clinical Trials

An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia

Lead Researcher: Kristen M O'Dwyer

This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).

View Study Details

Understanding Causes of Outcome Disparities in Adolescents and Young Adults (AYA) with Acute Lymphoclastic Leukemia (ALL)

Lead Researcher: Kristen M O'Dwyer

We will establish two prospective groups of patients with Acute Lymphoclastic Leukemia (ALL): "Cohort A" will be enrolled on the study at the time of diagnosis while "Cohort B" will be enrolled during maintenance chemotherapy.

View Study Details


Journal Articles

Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O'Dwyer KM, Liesveld JL, Mendler JH, Guzman M, Morrissette JD, Zhao J, Wang ES, Wetzler M, Jordan CT, Becker MW. "Evolution of acute myelogenous leukemia stem cell properties after treatment and progression." Blood.. 2016 Sep 29; 128(13):1671-8. Epub 2016 Jul 15.

Tyagi V, Alwaseem H, O'Dwyer KM, Ponder J, Li QY, Jordan CT, Fasan R. "Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs." Bioorganic & medicinal chemistry.. 2016 Sep 1; 24(17):3876-3886. Epub 2016 Jun 16.

O'Dwyer KM, Advani AS. "When to Treat Adults Like Children: Optimizing Therapy for Lymphoblastic Lymphoma in Young Adults." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 Feb 20; 34(6):533-8. Epub 2015 Dec 23.